Drawing for KABI PHARMACIA

USPTO serial 74357020

KABI PHARMACIA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
MANI, LALITHA
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with KABI PHARMACIA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Fred C. Philpitt

FRED C PHILPITT99 CANAL CTR PLZ STE 300ALEXANDRIA, VA 22314UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005pharmaceutical compounds and compositions; namely, pharmaceutical solutions for delivery of nutrients; volume replacement, irrigation and disinfection fluids; ophthalmological preparations; plasma; peptide hormones; smoking cessation preparations; autoimmunity preparations, preparations for the treatment of gastroenterological disorders; preparations for the treatment of urological disorders; preparations for the treatment of gynecology disorders; cardiovascular preparations; over-the-counter pharmaceuticals for use in the treatment of the common cold, coughs, hay fever, allergies, and mild states of pain; vitamins; antihistamines; allergy preparations; pain relief preparations; oncology preparations; preparations for use in the treatment of central nervous system disorders; medicated creams and ointments for the skin; general purpose disinfectants; medical diagnostic reagents; compounds and compositions for improving health and nutrition; namely, vitamins and nutritional supplements; sterile gauze and bandages; medical plasters and materials for dressings for dental use; material for dental wax; and preparations for treatment of plaque related diseasesABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (ABN6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Aug 9, 1994ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 8, 1994NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Nov 16, 1993PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 15, 1993NPUBNOTICE OF PUBLICATION—
Aug 19, 1993CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 22, 1993CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 14, 1993CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 29, 1993DOCKASSIGNED TO EXAMINER—
Apr 23, 1993DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance